Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Stok Raporu

Piyasa değeri: US$6.8b

Protagonist Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Protagonist Therapeutics CEO'su Dinesh Patel, Dec2008 tarihinde atandı, in görev süresi 17.5 yıldır. in toplam yıllık tazminatı $ 12.87M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.6% maaş ve 94.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.45% ine doğrudan sahiptir ve bu hisseler $ 30.43M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.4 yıl ve 11.4 yıldır.

Anahtar bilgiler

Dinesh Patel

İcra Kurulu Başkanı

US$12.9m

Toplam tazminat

CEO maaş yüzdesi5.56%
CEO görev süresi17.5yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi5.4yrs
Yönetim Kurulu ortalama görev süresi11.4yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • May 15

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • May 08

Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) last week reported its latest first-quarter results, which makes it a...
Seeking Alpha • Jan 30

Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide

Summary Protagonist Therapeutics remains a high-conviction buy, driven by late-stage assets icotrokinra and rusfertide approaching regulatory milestones in 2026. PTGX’s robust cash position of $678.8 million provides a runway through 2028, supporting aggressive R&D and upcoming commercialization efforts. Both icotrokinra and rusfertide have demonstrated strong efficacy and safety in pivotal trials, with regulatory submissions underway and significant market opportunities ahead. Valuation is premium at 21x EV/sales, reflecting high investor expectations for late-stage pipeline success; downside risk remains if approvals falter. Read the full article on Seeking Alpha
Analiz Makalesi • Oct 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shares have been powering on, with a gain...
Analiz Makalesi • Jun 13

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27%

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders would be excited to see that the share price has had a...
Seeking Alpha • Mar 11

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Summary Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk. Future PTGX prospects include expanding icotrokinra's use to Crohn's Disease and initiating phase 1 study for PN-881, targeting immune-mediated disorders like hidradenitis suppurativa. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Summary Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032. The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Summary Today, we circle back to the clinical stage of biopharma Protagonist Therapeutics, Inc., whose stock has tripled over the past year. The company has two late-stage drug candidates that are partnered with Takeda and Johnson & Johnson, respectively. If pivotal trials turn out to be successful, both drugs could be approved in 2026. Still more upside in this rally? An updated analysis of Protagonist Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Summary Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for polycythemia vera, faced a clinical hold from the FDA but had the hold removed in October 2021 and now looks approvable. Protagonist's joint plaque psoriasis candidate, JNJ-2113, showed positive results in a Phase 2 study, leading to a stock price increase. Both of Protagonist's lead candidates make a case for a commercial approval - although not for 2 more years at least, and there are risks, and hurdles still to be overcome. 2 Phase 3 studies must still be completed. The recently signed deal with Takeda to co-commercialise Rusfertide is a significant boost for Protagonist and has driven its market cap valuation to $1.64bn - I think that is an accurate reflection for its value for now, but may look to buy on any dips. Read the full article on Seeking Alpha
Seeking Alpha • Jun 08

Protagonist: Too Many Red Flags

Protagonist has recently faced a number of mishaps. These make the stock risky. They have a good deal of cash for now.
Seeking Alpha • Feb 01

Protagonist Is Still Being Undervalued Like There's Real Risk

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has been almost entirely resolved. The current valuation is still a deep discount from the highs prior to the dip.

CEO Tazminat Analizi

Dinesh Patel'un ücretlendirmesi Protagonist Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$115m

Dec 31 2025US$13mUS$716k

-US$130m

Sep 30 2025n/an/a

US$46m

Jun 30 2025n/an/a

US$52m

Mar 31 2025n/an/a

US$56m

Dec 31 2024US$9mUS$681k

US$275m

Sep 30 2024n/an/a

US$171m

Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Tazminat ve Piyasa: Dinesh 'nin toplam tazminatı ($USD 12.87M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 8.38M ).

Tazminat ve Kazançlar: Dinesh şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Dinesh Patel (69 yo)

17.5yrs
Görev süresi
US$12,871,506
Tazminat

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He serves as Additional Non-Execu...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Dinesh Patel
CEO, President17.5yrsUS$12.87m0.45%
$ 30.4m
Asif Ali
Executive VP & CFO4.2yrsUS$3.26m0.0040%
$ 271.7k
Arturo Molina
Chief Medical Officer3.6yrsUS$4.10m0.021%
$ 1.4m
Venkat Thalladi
EVP & Chief Technical Officerless than a yearVeri yokVeri yok
Newman Yeilding
Executive VP1.8yrsVeri yokVeri yok
Matthew Gosling
Executive VP and Chief Legal & Business Officer5.8yrsVeri yokVeri yok
Carena Spivey
Executive VP & Chief Human Resources Officer5.4yrsVeri yokVeri yok
Ashok Bhandari
EVP & Chief Discovery Officer5.4yrsVeri yokVeri yok
Carter King
Executive Vice President of Business Development5.2yrsVeri yokVeri yok
Abha Bommireddi
Executive VP & Chief of Staff5.4yrsVeri yokVeri yok
Samuel Saks
Clinical Development Advisor5.4yrsVeri yokVeri yok
5.4yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş

Deneyimli Yönetim: PTGX 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.4 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Dinesh Patel
CEO, President17.5yrsUS$12.87m0.45%
$ 30.4m
Harlan Weisman
Clinical Advisor11.4yrsVeri yokVeri yok
Lewis Williams
Independent Director9yrsUS$431.82k0.0080%
$ 543.3k
Chaitan Khosla
Chairman of Scientific Advisory Board11.4yrsUS$188.07kVeri yok
Harold Selick
Independent Chairman17.3yrsUS$428.07k0.090%
$ 6.2m
William Waddill
Independent Director9.9yrsUS$431.82k0.0080%
$ 543.3k
Charles Craik
Scientific Advisorno dataVeri yokVeri yok
Mark Gallop
Scientific Advisorno dataVeri yokVeri yok
Wayne Lencer
Clinical Advisorno dataVeri yokVeri yok
Aida Habtezion
Clinical Advisorno dataVeri yokVeri yok
Ellen Scherl
Clinical Advisorno dataVeri yokVeri yok
Bryan Giraudo
Independent Director8.1yrsUS$431.82k0.016%
$ 1.1m
11.4yrs
Ortalama Görev Süresi
69yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: PTGX 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/10 01:15
Gün Sonu Hisse Fiyatı2026/06/10 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Protagonist Therapeutics, Inc. 19 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Etzer DaroutBarclays
Evan SeigermanBMO Capital Markets Equity Research
Timothy ChiangCapital One Securities, Inc.